About Kyverna Therapeutics, Inc.
https://kyvernatx.comKyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases.
CEO
Warner Biddle
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 27
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
VIDA VENTURES ADVISORS, LLC
Shares:4.52M
Value:$41.44M
GILEAD SCIENCES, INC.
Shares:4.13M
Value:$37.8M
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC
Shares:3.37M
Value:$30.85M
Summary
Showing Top 3 of 81
About Kyverna Therapeutics, Inc.
https://kyvernatx.comKyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $38.31M ▼ | $-36.79M ▲ | 0% | $-0.85 ▲ | $-36.37M ▲ |
| Q2-2025 | $0 | $43.9M ▼ | $-42.08M ▲ | 0% | $-0.97 ▲ | $-41.55M ▲ |
| Q1-2025 | $0 | $46.91M ▲ | $-44.63M ▼ | 0% | $-1.03 ▼ | $-44.11M ▼ |
| Q4-2024 | $0 | $40.48M ▲ | $-37.49M ▼ | 0% | $-0.87 ▼ | $-36.9M ▼ |
| Q3-2024 | $0 | $9.58M | $-34.49M | 0% | $-0.8 | $-36.75M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $171.14M ▼ | $187.16M ▼ | $35.21M ▼ | $151.95M ▼ |
| Q2-2025 | $211.68M ▼ | $226.51M ▼ | $42.13M ▲ | $184.38M ▼ |
| Q1-2025 | $242.65M ▼ | $260.65M ▼ | $36.65M ▼ | $224.01M ▼ |
| Q4-2024 | $285.98M ▼ | $304.64M ▼ | $38.06M ▲ | $266.59M ▼ |
| Q3-2024 | $321.59M | $339.2M | $36.49M | $302.71M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-36.79M ▲ | $-43.32M ▼ | $22.56M ▼ | $1.49M ▲ | $-19.28M ▼ | $-43.71M ▼ |
| Q2-2025 | $-42.08M ▲ | $-31.95M ▲ | $29.17M ▲ | $-649K ▼ | $-3.43M ▲ | $-32.15M ▲ |
| Q1-2025 | $-44.63M ▼ | $-44.91M ▼ | $5.58M ▼ | $-414K ▼ | $-39.75M ▼ | $-44.91M ▼ |
| Q4-2024 | $-37.49M ▼ | $-37.06M ▼ | $29.22M ▲ | $-215K ▼ | $-8.04M ▲ | $-37.59M ▼ |
| Q3-2024 | $-34.49M | $-27.49M | $676K | $-152K | $-26.95M | $-27.59M |
CEO
Warner Biddle
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 27
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
VIDA VENTURES ADVISORS, LLC
Shares:4.52M
Value:$41.44M
GILEAD SCIENCES, INC.
Shares:4.13M
Value:$37.8M
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC
Shares:3.37M
Value:$30.85M
Summary
Showing Top 3 of 81